Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 3, 2007, Pages 342-356

  Zhang, Nan ^a   Khawli, Leslie A ^a,b   Hu, Peisheng ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

Author keywords

2B8; Apoptosis; CD20; chLym 1; HLA DR; Immunotherapy; Lym 1; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

CASPASE 3; CASPASE INHIBITOR; CD20 ANTIBODY; CYTOCHROME C; HLA DR ANTIGEN; HLA DR10 ANTIGEN; LIPOCORTIN 5; MONOCLONAL ANTIBODY LYM 1; PROPIDIUM IODIDE; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; LIPID RAFT; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; NICK END LABELING; NONHODGKIN LYMPHOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

EID: 34447538253     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.359.A     Document Type: Article

References (73)

1. Grillo-Lopez AJ, White CA, Dallaire BK, et al. The first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000;1:1.
2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825.
3. Hekman A, Honselaar A, Vuist WM, et al. Initial experience with treatment of human B-cell lymphoma with anti-CD 19 monoclonal antibody. Cancer Immunol Immunother 1991;32:364.
4. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18:385.
5. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin's lymphomas. Blood 2003;101:949.
6. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188.
7. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177.
8. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood 1987;69:584.
9. Reff ME, Carner K, Chambers KS, et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435.
10. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Indolent lymphoma: The single-agent pivotal trial. Semin Oncol 1999;26:79.
11. Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol 2002;29:81.
12. Cesano A, Gayko U. CD22 as a target of passive immunotherapy. Semin Oncol 2003;30:253.
13. Coleman M, Goldenberg DM, Siegel AB, et al. Epratuzumab: Targeting B-cell malignancies through CD22. Clin Cancer Res 2003;9:3991S.
14. 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 1992;52:6476.
15. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992;10:1696.
16. Pagel JM, Hedin N, Subbiah K, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003;101:2340.
17. de Kroon JF, de Paus RA, Kluin-Nelemans HC, et al. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B-cells in Scid mice. Exp Hematol 1996;24:919.
18. Shi JD, Bullock C, Hall WC, et al. In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B-cells. Leuk Lymphoma 2002; 43:1303.
19. Longo DL. DR's orders: Human antibody kills tumors by direct signaling. Nat Med 2002;8:781.
20. Nagy ZA, Hubner B, Lohning C, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med 2002;8:801.
21. Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830.
22. Liu C, DeNardo G, Tobin E, et al. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells. Cancer Biother Radiopharm 2004;19:545.
23. Chan CH, Wang J, French RR, et al. Internalization of the lymphocytic surface protein CD22 is controlled by a novel membrane proximal cytoplasmic motif. J Biol Chem 1998;273:27809.
24. Shan D, Press OW. Constitutive endocytosis and degradation of CD22 by human B-cells. J Immunol 1995; 154:4466.
25. Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties. Clin Cancer Res 2003;9:3982S.
26. Hu P, Glasky MS, Yun A, et al. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hum Antibodies Hybridomas 1995;6:57.
27. Lechler RI, Simpson SE, Bach F. Major and minor histocompatibility antigens. In: Bach F, Auchincloss H., eds. Transplantation Immunology. New York: Wiley-Liss, 1995.
28. Rose LM, Gunasekera AH, DeNardo SJ, et al. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996;43:26.
29. Rose LM, Deng CT, Scott SL, et al. Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol Immunol 1999;36:789.
30. DeNardo GL. The next generation of imaging and therapeutic agents for lymphoma and chronic lymphocytic leukemia. New Perspect Cancer Diagn Manag 1995; 3:76.
31. 131I-Lym-1 antibody. Cancer Biother Radiopharm 1998;13:239.
32. I-131I-LYM-1 monoclonal antibodies. Int J Biol Markers 1987;2:49.
33. 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl 1988;3:96.
34. 131I-Lym-1. Cancer Res 1990;50:1014S.
35. DeNardo GL, Lewis JP, DeNardo SJ, et al. Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 1994;73:1425.
36. 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study. Anticancer Res 1998;18:2779.
37. 131I-Lym-1 antibody (100% Lym-1 reactive). Cancer Biother Radiopharm 1998;13: 239.
38. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3246.
39. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity, and tumor regression in patients with lymphoma. J Nucl Med 1999;40:302.
40. 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med 1999; 40:1317.
41. 131I-labeled Lym-1 antibody. Comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res 1999;5:533.
42. DeNardo GL, O'Donnell RT, Rose LM, et al. Milestones in the development of Lym-1 therapy. Hybridoma 1999;18:1.
43. 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: Loss of tumor specificity due to radiolysis. Cancer Biother Radiopharm 2000;15:547.
44. Hu E, Epstein AL, Naeve GS, et al. A phase la clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B-cell malignancies. Hematol Oncol 1989;7:155.
45. Ottonello L, Epstein AL, Dapino P, et al. Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor: Intervention of FcgammaRII (CD32), CD11b-CD18 integrins, and CD66b glycoproteins. Blood 1999; 93:3505.
46. Ottonello L, Morone P, Mancini M, et al. FMLP- and TNF-stimulated monoclonal Lym-1 antibody-dependent lysis of B lymphoblastoid tumour targets by neutrophils. Br J Cancer 1999;80:331.
47. Ottonello L, Epstein AL, Mancini M, et al. Monoclonal Lym-1 antibody-targeted lysis of B lymphoma cells by neutrophils: Evidence for two mechanisms of FcgammaRII-dependent cytolysis. J Leuk Biol 2000; 68:662.
48. Ottonello L, Epstein AL, Mancini M, et al. Chimaeric Lym-1 monoclonal antibody-mediated cytolysis by neutrophils from G-CSF-treated patients: Stimulation by GM-CSF and role of Fc gamma-receptors. Br J Cancer 2001;85:463.
49. Mone AP, Huang P, Pelicano H, et al. Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood 2004;103:1846.
50. Bains SK, Mone A, Yun Tso J, et al. Mitochondria control of cell death induced by anti-HLA-DR antibodies. Leukemia 2003;17:1357.
51. Drenou B, Blancheteau V, Burgess DH, et al. A caspase-independent pathway of MHC class II antigen-mediated apoptosis of human B lymphocytes. J Immunol 1999;163:4115.
52. Kostelny SA, Link BK, Tso JY, et al. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer 2001;93:556.
53. Muppidi JR, Siegel RM. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T-cell death. Nat Immunol 2004;5:182.
54. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: Signalling through lipid rafts. Immunology 2002;107:176.
55. Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 2000;275:17221.
56. Bouillon M, El Fakhry Y, Girouard J, et al. Lipid raft-dependent and -independent signaling through HLA-DR molecules. J Biol Chem 2003;278:7099.
57. Zhang N, Khawli LA, Hu P, et al. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res 2005;11:5971.
58. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B-cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91:1644.
59. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-rituximab-induced apoptosis of malignant human B-cells. Cancer Immunol Immunother 2000;48:673.
60. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000;26:133.
61. van der Kolk LE, Evers LM, Omene C, et al. CD20-induced B-cell death can bypass mitochondria and caspase activation. Leukemia 2002;16:1735.
62. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754.
63. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940.
64. O'Reilly CM, Fogarty KE, Drummond RM, et al. Quantitative analysis of spontaneous mitochondrial depolarizations. Biophys J 2003;85:3350.
65. Scaduto RC, Jr, Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 1999;76:469.
66. DeNardo GL. The next generation of imaging and therapeutic agents for lymphoma and chronic lymphocytic leukemia. Meniscus 1995;3:76.
67. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 2002;99:1038.
68. Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell 1994;78:539.
69. Friesen C, Herr I, Krammer PH, et al. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996;2:574.
70. Fulda S, Susin SA, Kroemer G, et al. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 1998;58:4453.
71. Held KD. Radiation-induced apoptosis and its relationship to loss of clonogenic survival. Apoptosis 1997;2: 265.
72. 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm 2001;16:213.
73. Leist M, Jaattela M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001;2:589.